First day of trading in stem cell company NextCell Pharma AB

NextCell Pharma AB (”NextCell”) announces today that trading with its shares and warrants of series TO 1 will commence today at the AktieTorget stock exchange. The shares will be traded under the name “NEXTCL” with the corresponding ISIN code SE009723125. The warrants will be designated with the name “NEXTCL TO 1” and ISIN code SE009888795. 

NextCell develops stem cell therapies, where stem cells from donated umbilical cords can treat patients who are not family of the donor. The cells are developed with NextCell's proprietary method and the company's first product, ProTrans™, is intended for use in diabetes as well as kidney transplantation.

- We are currently working on completing an application to the Medical Products Agency to test ProTrans ™ in a first clinical trial on diabetic patients, says CEO Mathias Svahn. If ProTrans™ works, as intended, i.e. if it can - perhaps in combination with other drugs - cure the disease, the product could become a blockbuster, Svahn continues.

In parallel with the development of ProTrans™ the company operates Cellavia, a service for family-saving of stem cells from the umbilical cord. Access to one´s-own or one’s siblings frozen umbilical stem cells may be crucial in the treatment of several serious diseases including some partial hereditary immunological and blood cancer diseases at different stages of their life. "Because I have diabetes in the family, I have let savemy relatives’ umbilical stem cells when possible," said Anders Essen-Möller, chairman of NextCell.

Terms of warrants of series TO 1 in brief
Holdings of one (1) warrant TO 1 entitles the holder to subscribe for one (1) newly issued share at a price of 5.00 SEK. Subscription of shares using warrants will take place during the period 23 August 2018 through September 13, 2018, by means of payment before September 13, 2018.

Financial advisor
Sedermera Fondkommission is financial adviser to NextCell Pharma AB in conjunction with the listing on AktieTorget.


For more information on NextCell Pharma AB, please contact:

Mathias Svahn, CEO

Phone: 0702-615 504

E-mail: mathias.svahn@nextcellpharma.com 

www.nextcellpharma.com och www.cellaviva.se 

About NextCell Pharma AB:

Stem cells are expected to change the way how many of today's life-threatening diseases are treated. NextCell Pharma AB develops ProTrans™, a drug candidate consisting of stem cells for the primary treatment of autoimmune and inflammatory diseases as well as for use in kidney transplants. ProTrans™ consists of selected stem cells derived from the umbilical cord tissue with NextCell Pharma AB's proprietary method. In addition, the company has a service called Cellaviva, Sweden's first and only IVO-approved stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue.

Subscribe

Documents & Links